BRIEF—ReCode Therapeutics adds further $120 million funding

Texas, USA-based mRNA genetic medicines company ReCode Therapeutics today announced the close of a Series B extension financing round, co-led by new investors, Leaps by Bayer, the impact investment unit of Germany’ Bayer, AyurMaya, an affiliate of Matrix Capital Management, and with participation from Amgen Ventures.

With the additional $120 million in new financing, the company has secured a total of $200 million in Series B funding.

In connection with the financing, Dr Alan Colowick, managing director of Matrix, and Rakhshita Dhar, senior director of Venture investments Health at Leaps by Bayer, will join ReCode’s board of directors.

The initial Series B financing announced in October 2021 was co-led by Pfizer Ventures and EcoR1 Capital and included Sanofi Ventures, Orbimed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures, Osage University Partners, Tekla Capital Management, Superstring Capital, and NS Investment.

Proceeds from the financing will be used to fund the diversification of ReCode’s pipeline into central nervous system (CNS), liver, and oncology indications, while continuing to advance ReCode’s lead mRNA programs for primary ciliary dyskinesia (PCD) and cystic fibrosis (CF) into the clinic.